Abstracts tagged "azathioprine"

Abstract Number: 0887 • ACR Convergence 2021
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Chrisanna Dobrowolski¹, Jiandong Su², John McGinley¹, Melissa Fazzari¹, Kathleen Bingham³, Nicole Anderson², Dorcas Beaton⁴, Lesley Ruttan³, Joan Wither², Maria Tartaglia², Mahta Kakvan², Dennisse Bonilla², May Choi⁵, Marvin Fritzler⁶, Patricia Katz⁷, Robin Green², Chaim Putterman¹ and Zahi Touma⁸, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Health Network, Toronto, ON, Canada, ³University of Toronto, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of California San Francisco, San Francisco, CA, ⁸University of Toronto, Mississauga, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments…
Abstract Number: 1963 • 2019 ACR/ARP Annual Meeting
Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice
Prathima Anandi ¹, Alyson Dickson ², Qiping Feng ¹, Wei-Qi Wei ², William Dupont ², Dale Plummer ², Ge Liu ¹, Katherine Barker ², Vivian Kawai ², Kelly Birdwell ², Nancy Cox ¹, C. Michael Stein ², Adriana Hung ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Azathioprine is a widely-used drug for the treatment of rheumatic diseases, inflammatory bowel disease, and for organ transplantation. However, treatment is often limited by…
Abstract Number: 1568 • 2018 ACR/ARHP Annual Meeting
Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study
Barkha Amlani¹, Umang Barvalia², Ghada Metwally Ahmed Elsayed³, Jeffrey P. Kanne⁴, Zhanhai Li⁵ and Sara S. McCoy⁶, ¹Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Pulmonary And Critical Care, university of wisconsin Hospital and clinics, Madison, WI, ³Rheumatology, University of Wisconsin Hospital and clinics, Madison, WI, ⁴Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Interstitial lung disease (ILD) is a common extraglandular manifestation of Sjögren’s syndrome (SS). There is a paucity of literature on the management of SS-ILD.…
Abstract Number: 1747 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, François Lifermann⁴, Loïk Geffray⁵, Thomas Quémeneur⁶, Jean-Luc Saraux⁷, Marie Wislez⁸, Vincent Cottin⁹, Marc Ruivard¹⁰, Nicolas Limal¹¹, Achille Aouba¹², Bernard Bonnotte¹³, Antoine Neel¹⁴, Christian Agard¹⁵, Pascal Cohen¹⁶, Benjamin Terrier¹⁷, Claire Le Jeunne¹⁷, Luc Mouthon¹, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group¹⁷, ¹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hôtel Dieu, Paris, France, ⁴Dax, Dax, France, ⁵Lisieux, Lisieux, France, ⁶Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁷Eaubonne, Eaubonne, France, ⁸Paris Tenon, Paris, Gambia, ⁹Lyon Louis Pradel, Lyon, France, ¹⁰Clermont-Ferrand, Clermont Ferrand, France, ¹¹Créteil Henri Mondor, Créteil, France, ¹²Caen, Caen, France, ¹³Dijon, Dijon, France, ¹⁴Medecine Interne, Nantes Hôtel Dieu, Nantes, France, ¹⁵Nantes Hôtel Dieu, Nantes, France, ¹⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: At month 24 (M24), CHUSPAN2-trial patients with nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), who received 1 yr of azathioprine (AZA) and glucocorticoids (GC) as…
Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Annalisa Montante¹, Alicia Le Bras², Benjamin Terrier³, Pascal Cohen³, Xavier Puéchal⁴, Alexandre Karras⁵, Philippe Ravaud⁶, Loïc Guillevin⁷ and Isabelle Durand-Zaleski⁸, ¹UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ²UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁵Nephrology, HEGP, Paris, France, ⁶Hôpital Hôtel Dieu, Paris, France, ⁷Internal medicine, Cochin University Hospital, paris, France, ⁸UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
Abstract Number: 1782 • 2017 ACR/ARHP Annual Meeting
Mycophenolic Acid Decreases IL-10 and IL-6 Production By B Cells of Granulomatosis with Polyangiitis Patients and Healthy Controls in Vitro
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a relapsing autoimmune disease affecting small- to medium-sized blood vessels. B cells are thought to play an important antibody-independent…
Abstract Number: 1172 • 2016 ACR/ARHP Annual Meeting
Azathioprine and Mycophenolate Mofetil Adherence in a Nationwide Medicaid Cohort with Systemic Lupus Erythematosus
Candace H. Feldman¹, Jamie E. Collins², Zhi Zhang³, Ichiro Kawachi⁴, Daniel H. Solomon⁵ and Karen H. Costenbader⁶, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, ⁵Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Azathioprine (AZA) and mycophenolate mofetil (MMF) are commonly used immunosuppressants for moderate-to-severe SLE. Overall adherence among SLE patients has been shown to be poor…
Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months
Benjamin Terrier¹, Christian Pagnoux², Elodie Perrodeau³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quémeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal¹⁵, Luc Mouthon¹⁵, Philippe Ravaud¹⁶ and Loïc Guillevin¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵CHU Lyon, Lyon, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, Cochin Hospital, Paris, France, ⁸Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹³Internal Medicine, Centre Hospitalier, Niort, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Hôpital Hôtel Dieu, Paris, France
Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
Abstract Number: 2956 • 2016 ACR/ARHP Annual Meeting
Optimization of Thiopurines with a Xanthine Oxidase Inhibitor in Patients with Autoimmune Systemic Diseases
Mériem Belhocine¹, Aurélie Chapdelaine¹, Maxime Doré², Yves Troyanov³ and Anne-Marie Mansour¹, ¹medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ²Pharmacy, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ³Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada
Background/Purpose: Thiopurines are a mainstay for the treatment of autoimmune diseases. However, in inflammatory bowel diseases (IBD), 14-18 % of patients manifest a skewed metabolism…
Abstract Number: 883 • 2015 ACR/ARHP Annual Meeting
Evaluation of Thiopurine Metabolites Monitoring in Patients Treated with Azathioprine for Rheumatic Diseases
Aurélie Chapdelaine¹, Maxime Doré², Yves Troyanov³ and Anne-Marie Mansour¹, ¹Internal Medicine, Université de Montréal, Montréal, QC, Canada, ²Pharmacy, Université de Montréal, Montréal, QC, Canada, ³Rheumatology, Université de Montréal, Montréal, QC, Canada
Background/Purpose: The thiopurine azathioprine (AZA) is an inactive pro-drug that undergoes complex metabolic transformations leading to the formation of 6-thioguanine nucleotide (6-TGN), the active metabolite,…
Abstract Number: 1086 • 2015 ACR/ARHP Annual Meeting
Does Adding Azathioprine to Glucocorticoid Induction Increase the Remission Rate and Prevent Relapses in Patients with Systemic Necrotizing Vasculitides without Poor-Prognosis Factors? a Multicenter, Double-Blind Randomized Controlled Trial
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, Thomas Quémeneur⁴, Antoine Néel⁵, Christian Agard⁵, François Lifermann⁶, Eric Liozon⁷, Marc Ruivard⁸, Pascal Godmer⁹, Nicolas Limal¹⁰, Arsène Mékinian¹¹, Thomas Papo¹², Anne-Marie Ruppert¹³, Anne Bourgarit-Durand¹⁴, Boris Bienvenu¹⁵, Loïck Geffray¹⁶, Jean-Luc Saraux¹⁷, Elisabeth Diot¹⁸, Bruno Crestani¹², Xavier Delbrel¹⁹, Laurent Sailler²⁰, Pascal Cohen¹, Véronique Le Guern²¹, Benjamin Terrier¹, Matthieu Groh²¹, Claire Le Jeunne²¹, Luc Mouthon²¹, Philippe Ravaud³ and Loïc Guillevin for The French Vasculitis Study Group²¹, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Hôpital Hôtel Dieu, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Nantes, Nantes, France, ⁶CH Dax, Dax, France, ⁷CHU Limoges, Limoges, France, ⁸CHU Clermont-Ferrand, Clermont–Ferrand, France, ⁹CH Vannes, Vannes, France, ¹⁰CHU Créteil, Créteil, France, ¹¹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ¹²CHU Bichat, Paris, France, ¹³CHU Tenon, Paris, France, ¹⁴CHU Bondy, Bondy, France, ¹⁵Internal Medicine, Hospital Caen, Caen, France, ¹⁶CH Lisieux, Lisieux, France, ¹⁷CH Eaubonne, Eaubonne, France, ¹⁸CHU Tours, Tours, France, ¹⁹CH Pau, Pau, France, ²⁰CHU Toulouse, Toulouse, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Glucocorticoids (GC) achieve remission in most patients with systemic necrotizing vasculitides (SNVs) without poor-prognosis factors based on the 1996 Five-Factor Score (FFS; comprising creatininemia…
Abstract Number: 3160 • 2015 ACR/ARHP Annual Meeting
Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Daniel H. Solomon¹, Seoyoung C. Kim⁶ and Karen H. Costenbader⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk of infections partly from use of immunosuppressives (IS). Clinical trials are powered to detect…
Abstract Number: 1782 • 2014 ACR/ARHP Annual Meeting
Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Pascal Cohen², Boris Bienvenu⁴, Kim Heang Ly⁵, Alain Bruet⁶, Brigitte Gilson⁷, Marc Ruivard⁸, Edouard Pertuiset⁹, Mohamed Hamidou¹⁰, Benjamin Terrier², Christian Pagnoux¹¹, Luc Mouthon², Loic Guillevin¹² and The French Vasculitis Study Group (FVSG)¹², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Médecine interne, CHU Côte de Nacre, CAEN, France, ⁵CHU Dupuytren, Limoges, Limoges, France, ⁶Department of Nephrology and Internal Medicine, CH de Poissy Saint-Germain-en-Laye, Poissy, France, ⁷Department of Nephrology and Internal Medicine, CH de Verdun, Verdun, France, ⁸CHU Estaing, Clermont–Ferrand, Clermont–Ferrand, France, ⁹Rheumatology, René Dubos Hospital, Pontoise, France, ¹⁰CHU Hôtel Dieu, Nantes, Nantes, France, ¹¹Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose To study the long-term outcomes of 65 patients with non-HBV polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) enrolled in a prospective, randomized, open-label trial,1…
Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 958 • 2014 ACR/ARHP Annual Meeting
The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Long-term Immunosuppression of Lupus Nephritis
Farah Tamirou¹, David D'Cruz², Shirish Sangle³, Philippe Remy⁴, Carlos Vasconcelos⁵, Christoph Fiehn⁶, Maria del Mar Ayala Gutierrez⁷, Inge-Margrethe Gilboe⁸, Maria Tektonidou⁹, Daniel Blockmans¹⁰, Isabelle Ravelingien¹¹, Véronique le Guern¹², Geneviève Depresseux¹, Loïc Guillevin¹³, Ricard Cervera¹⁴ and Frédéric A. Houssiau¹⁵, ¹Pôle de Pathologies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium, ²Rheumatology, Louis Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ³Lupus Unit, St Thomas' Hospital, London, United Kingdom, ⁴Service de Néphrologie et de Transplantation, Hôpital Henri Mondor, Créteil, France, ⁵Imunologia Clinica - M Interna, Hospital Geral Santo Antonio, Porto, Portugal, ⁶ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ⁷General Internal Medicine, Hospital Regional Universitario Carlos Haya, Malaga, Spain, Malaga, Spain, ⁸Rheumatology unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁹First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ¹⁰Rheumatology, UZ Leuven, Leuven, Belgium, ¹¹Rheumatology, Onze-Lieve-Vrouwzienkenhuis, Aalst, Belgium, ¹²Internal Medicine, Hôpital Cochin, Paris, France, ¹³Internal Medicine, Hôpital Cochin, University Paris V Descartes, Paris, France, ¹⁴Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain, ¹⁵Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium
Background/Purpose Very longterm data are rarely reported in lupus nephritis (LN) trials, despite their pivotal importance to detect late poor renal outcomers and to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].